Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of T-cell therapies designed for patients with B-cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-184.12M |
| Operating Margin | 0.00% |
| Return on Equity | -93.20% |
| Return on Assets | -48.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.26 |
| Price-to-Book | 1.77 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -3.44 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $169.54M |
| Float | $141.48M |
| % Insiders | 0.97% |
| % Institutions | 94.44% |
Volatility is currently contracting
Cabaletta Bio is rated Buy, trading 40% below its $2.41 pipeline value despite a single-asset risk profile. CABA's lead CAR T asset, rese-cel, targets severe autoimmune diseases with pivotal Phase 1/2 data expected mid-2027 and BLA submission planned for late 2027. A recent 10-year manufacturing deal with Cellares lowers future COGS, supporting margin expansion if rese-cel is approved.
PHILADELPHIA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced the grant of inducement equity awards to four newly hired non-executive employees as a material inducement to commencing their employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
PHILADELPHIA, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its participation in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference: Meetings with investors on Tuesday, September 8, 2026, in Boston, MA.
Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel
Cabaletta Bio (CABA) offers a de-risked, breadth-first CAR-T platform for autoimmune diseases, with strong EULAR 2026 data and a compelling $2.90/share entry point. CABA's rese-cel is advancing across five indications, with pivotal myositis and systemic sclerosis trials, clean safety profile, and automated manufacturing via Cellares. Recent $150M raise with participation from Eli Lilly and top biotech funds strengthens CABA's financial runway and strategic optionality, supporting a 2H27 BLA timeline.
Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through latest follow-up, as long as 1.5 years
Here is how Cabaletta Bio, Inc. (CABA) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CABA and any ticker you trade — then tracks every position and per-strategy win rate.
